Tryptamine TherapeuticsEXOPF
13F holders, Q2 2025 (June 30)1holders
1new positions
0sold out
$0.02avg. 13F price*
At the end of Q2 2025, 1 institutions reported holding Tryptamine Therapeutics Ltd. (EXOPF) in their 13F filings, unchanged from Q4 2024. 1 opened new positions and 0 sold out. The largest holder was Financially Speaking Inc ($7K).
- Company
- Tryptamine Therapeutics Ltd.
- CUSIP
- Q9240A100
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $7K |
| Exits | 0 | $0 |
All 13F filers, Q4 2024 → Q2 2025: 361,600 shares bought, net +361,600 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| Financially Speaking Inc | 0.00% | New | 361,600 | $7K |
"% of holder's portfolio" is EXOPF's weight in each manager's 13F, not the share of Tryptamine Therapeutics Ltd. the manager owns.